Maravai LifeSciences Holdings, Inc. (MRVI) Return on equity 2019–2025
Maravai LifeSciences Holdings, Inc. (MRVI) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-61.6%FY2025 · since FY2019: -3.1% → -61.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -61.6% | -17.0 pp |
| FY2024 | -44.5% | -16.0 pp |
| FY2023 | -28.6% | -68.9 pp |
| FY2022 | 40.4% | -17.3 pp |
| FY2021 | 57.7% | -42.8 pp |
| FY2020 | 100.5% | +103.6 pp |
| FY2019 | -3.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More MRVI financial trends
MRVI RevenueMRVI Net incomeMRVI Net marginMRVI Gross profitMRVI Gross marginMRVI Operating incomeMRVI Operating marginMRVI Operating cash flowMRVI Free cash flowMRVI Capital expendituresMRVI Stock buybacksMRVI Dividends paidMRVI Total assetsMRVI Total liabilitiesMRVI Shareholders’ equityMRVI overview →